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Abstract
Background: A previous suicide attempt is a potent risk factor for suicide later on. Crisis
intervention, psychiatric and psychosocial evaluation at emergency medical facilities, and follow-up
care for suicide attempters are considered important components for suicide prevention. The
Japanese Multimodal Intervention Trials for Suicide Prevention (J-MISP) includes a randomized,
controlled, multicenter trial of post-suicide attempt case management for the prevention of further
attempts (ACTION-J) to address the continuing increase in suicides in Japan. The primary aim of
ACTION-J is to examine the effectiveness of an extensive intervention for suicide attempters in
prevention of recurrent suicidal behavior, as compared with standard intervention. This paper
describes the rationale and protocol of the ACTION-J trial.
Methods/Design: In this clinical trial, case management intervention will be provided at 19
emergency medical facilities in Japan. After crisis intervention including psychiatric evaluation,
psychosocial assessment, and psychological education, subjects will be randomly assigned to either
a group receiving continuous case management or a control group receiving standard care. Suicidal
ideation, depressive symptoms, and general health condition will be evaluated as secondary
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BMC Public Health 2009, 9:364 http://www.biomedcentral.com/1471-2458/9/364measures. The intervention was initiated in July 2006. By December, 2009, 842 subjects will be
randomized. Subject follow-up will continue for 1.5 to 5 years.
Discussion: Suicide is a complex phenomenon that encompasses multiple factors. Case
management by multi-sector collaboration is needed. ACTION-J may provide valuable information
on suicide attempters and may develop effective case management to reduce future risk for suicide
attempters.
Trial registration: UMIN Clinical Trials Registry number, UMIN000000444. ClinicalTrials.gov
number, NCT00736918.
Background
A history of suicide attempt as a risk factor for suicide
Based on studies in Europe, North America, and Australa-
sia, a previous suicide attempt is a key risk factor for com-
pleted suicide [1-3]. After a follow-up period of 1 year,
12% to 15% of repetitions of cases of self-harm or suicide
attempt are non-fatal, whereas 0.8% to 2.6% are fatal.
After a follow-up period of 9 years, 3% to 12% ended in
completed suicide [4]. Given these statistics, intervention
for suicide attempters is an important element to prevent
suicide.
Recent increase in suicides in Japan
For approximately two decades (from 1978 to 1997), the
suicide rate in Japan has been between 17.0 and 21.0 per
100,000 people. In 1997, 24,931 suicides were reported
in Japan. In 1998, a dramatic 1.35-fold increase in the
number of suicides in Japan occurred, as 32,863 suicides
were reported. Since 1998, suicide rates in Japan have
been between 25.2 and 27.0 per 100,000 people. For 11
years, the annual number of suicides in Japan has
remained over 30,000 [5]. According to statistics from the
World Health Organization (WHO) compiled in 2007
concerning worldwide suicide rates, the suicide rate in
Japan was the eighth highest in the world [6].
Recent preventive measures against suicide in Japan
"The Declaration of Suicide Prevention" was issued in
2002 in Japan by the Advisory Panel on Strategy for Sui-
cide Prevention. Since 2002, various measures associated
with suicide prevention have been implemented, such as
publication of suicide prevention manuals for the work
place and medical practitioners. However, the number of
suicides has not yet declined significantly. Therefore, in
2005, an intensive deliberation on suicide prevention was
held by the Health, Labour, and Welfare Committee in the
House of Councillors, and "The Resolution on Urgent and
Effective Promotion of Comprehensive Strategies for Sui-
cide" was passed in July 2005.
Also in 2005, two research projects (Japanese Multimodal
Intervention Trials for Suicide Prevention: J-MISP [7])
funded by The Japanese Ministry of Health, Labor and
Welfare (JMHLW), were launched to develop effective
strategies to prevent suicide. J-MISP consists of a commu-
nity intervention trial of a multimodal suicide prevention
program (NOCOMIT) [8] and a randomized controlled
multicenter trial of post-suicide attempt case management
to prevent further attempts (ACTION-J).
Review of strategies of intervention for suicide attempters
Various studies on intervention for suicide attempters as
well as systematic reviews of these studies have been
reported [9-14]. Few randomized controlled trials that
focused on intervention methods showed a significant
decrease in the repetition rate for attempted suicide. Van
Herringen and colleagues investigated the effects of vari-
ous strategies to increase compliance with referrals for
outpatient aftercare [9]. Twenty-one of 196 patients
(10.7%) in the experimental group and 34 of 195 patients
(17.4%) in the control group repeated their suicidal
behavior. The odds ratio was 0.57 (95% CI: 0.32 to 1.02).
A summary of 5 studies comparing cognitive behavioral
therapy with standard aftercare demonstrated an odds
ratio of 0.70 (confidence interval, 0.45 to 1.11), indicat-
ing the effects on suicide prevention. A summary of 6
studies involving intensive outreach, brief inpatient treat-
ment, and nursing care, as compared with standard care,
produced the odds ratio of 0.83 (CI: 0.61 to 1.14) [12].
Small sample sizes in the primary studies selected for the
systematic review resulted in a wide range of confidence
intervals for the odds ratios. Fewer than 600 subjects in
both the experimental and control groups participated in
the 5 studies to evaluate cognitive behavioral therapy and
the 6 studies to investigate the effects of outreach pro-
grams. Thus, the total number of subjects in these studies
was under 1,200. In addition, the follow-up period after
enrollment was only 6 to 12 months. Hawton and col-
leagues [11] and Gaynes and colleagues [13], noting the
limitations of studies with too few subjects and too short
a study period, emphasized the need for large trials atPage 2 of 11
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ventions.
Overall scheme of ACTION-J
The act of suicide is complex. Findings from previous psy-
chological autopsy studies in other countries indicate that
more than 80% of patients who completed suicide could
be diagnosed with a psychiatric disorder [15,16]. Over
80% of highly lethal (incomplete) suicide attempters
taken to emergency medical centers in Japan were diag-
nosed with axis I psychiatric disorders, according to the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) [17]. Proper psychiatric assessment and treat-
ment of suicide attempters may be critical to suicide pre-
vention.
Based on these findings, we chose to utilize emergency
medical facilities as trial sites and designed an interven-
tion trial involving close collaboration between emer-
gency medicine and psychiatric medicine for
management of suicide attempters with psychiatric disor-
ders. We planned a large-scale, multisite study in Japan.
In this trial, case management is employed as an interven-
tion method. Case management provides multi-dimen-
sional and comprehensive care that has not been studied
in previous research, and includes psychological educa-
tion, follow-ups to increase compliance with referrals for
outpatient treatment, individualized casework including
coordination of use of social resources, and information
technology-based services. Prevention of further suicide
attempts will be compared between subjects in the exper-
imental group who receive the specialized, case manage-
ment care and subjects in the control group who receive
standard care.
Objective of this study
The objective of this study is to examine the effectiveness
of a trial intervention to prevent recurrent suicidal behav-
ior by suicide attempters in Japan, as compared with a
control intervention. It is expected that the case manage-
ment administered in this study will be effective to pre-
vent recurrence of suicide attempts.
Methods/Design
ACTION-J is an open, randomized, controlled, multi-
center study which examines the effectiveness of a trial
intervention for suicide attempters in Japan. The trial
intervention involves the implementation of case man-
agement for suicide attempters transported and admitted
to emergency medical facilities. The task schedule is pre-
sented in Table 1.
Organization
JMHLW selected the Japan Foundation for Neuroscience
and Mental Health (JFNMH) as the primary institution
responsible for J-MISP, in close collaboration with the
National Center of Neurology and Psychiatry. The J-MISP
administration office in JFNMH will organize overall
administrative procedures regarding the operations of the
ACTION-J study group. The office will also establish and
operate the steering committee, central research ethics
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◎
Actions to critical 
situations
In both groups during the study as occasions require
Reports of a serious 
adverse event
Prompt report to the director of the hospital and the study group management office in both groups as occasions require
◎ : implemented in both groups; ○ : implemented only in experimental intervention group
*: Psychoeducation Program I to all participants in both groups
**: Psychoeducation Program II to their family members during hospitalization in the experimental group
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progress control committee.
The ACTION-J study group will include 19 participating
hospitals in Japan. The study group will comprise the fol-
lowing: the study group management office, each partici-
pating hospital, the steering committee, the principal
statistician, the independent statistician, the intervention
program committee, the event review committee, and the
data management center for technical support.
Each participating hospital will have psychiatrists, emer-
gency department physicians, case managers, and other
personnel. In addition, one coordinator, either a psychia-
trist or an emergency physician, will be assigned to each
participating hospital. Other participating researchers in
this study include experts in suicide prevention, nurses,
clinical psychologists, psychiatric social workers, biostat-
isticians, epidemiologists, and coordinators of the data
management center.
Subjects
Subjects will include individuals who are admitted to
emergency medical facilities in Japan, are evaluated by an
emergency physician or a psychiatrist in the emergency
department, and are diagnosed as having made a suicide
attempt. Subjects must also meet the following inclusion
criteria:
Inclusion criteria
1) Subject is over 20 years old.
2) Subject has been diagnosed with a psychiatric disorder
classified into DSM-IV axis I.
3) Subject has had suicidal intentions confirmed at least
twice using the Suicide Intent Scale [18].
4) Subject is able to understand the description of the
study and provide informed consent.
5) During hospitalization, subject is able to attend an
interview and the Psychoeducation Program I (see Interven-
tion section), which will be required before enrollment in
the study.
6) Subject is able to visit the participating hospital regu-
larly for evaluations and case management and be con-
tacted directly from the hospital on a regular basis.
Exclusion criterion
1) Individual has a primary diagnosis that is not classified
into DSM-IV axis I.
Estimation of sample size
The total sample size is 842 participants, including 421
participants in each of the two treatment groups. Calcula-
tion of the desired sample size was based on the following
rationale. According to a study of suicidal individuals
transported to psychiatric emergency facilities in Japan,
the annual incidence rate of events (including death) was
set at 15% in the control group [19]. The target reduction
in recurrent suicidal behavior in the trial intervention
group was set at approximately 30%; the annual incidence
rate of events (including death) in the intervention group
was estimated to be 10.5% [20].
Based on this estimation, we calculated the sample size
using the method of Shoenfeld and Richter, in order to
confirm that the intervention group is superior, with a sig-
nificance level of 2.5% for the one-sided test and a power
of 90%, dependent on a 3.5-year-enrollment period and a
1.5-year follow-up period after enrollment. Given these
assumptions, the desired number of participants per
group was calculated to be 518, and number of events was
expected to be 296. Sample size was set to increase the
likelihood that the expected number of events (≥ 90% if
no participant is lost to follow-up) would be observed
during the study period.
Informed consent
Participants will be patients admitted to the participating
hospitals on an emergency basis, those who meet the
inclusion criteria, and who provide informed consent to
participate in this study.
Enrollment
Participant enrollment will be based on the following
procedural outline (Figure 1). Any physician in an emer-
gency facility will contact a psychiatrist when suspecting
that a patient has made a suicide attempt. The psychiatrist
will collect information and make a psychiatric diagnosis
when examining the patient. At this point, the patient's
suicidal intention will be confirmed (first check for sui-
cidal intention). The investigator will confirm that the
patient has not yet participated in this trial (i.e., that this
event is not a repetition of suicidal behavior of a partici-
pant already enrolled in this trial) and will determine
whether the patient is eligible to participate in this study
by reviewing the inclusion and exclusion criteria. The
investigator will explain this study, as well as the Psychoed-
ucation Program I (see the description in the Intervention
section), to a patient who is confirmed to have suicidal
intentions and obtain patient consent. Next, a practitioner
in charge of the psychoeducation program will provide
the Psychoeducation Program I to the patient.Page 4 of 11
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of a patient who is deemed eligible to participate in the
study. After the patient completes the Psychoeducation Pro-
gram I, the investigator will reconfirm the suicidal inten-
tions of a patient who is deemed eligible to participate in
the study (second check for suicidal intention). The inves-
tigator will obtain written consent from the patient to par-
ticipate in this study. On-site research staff at the
participating hospital will collect data from the partici-
pant at the time of enrollment and enter the information
via a web input system to receive a random assignment.
The participant will be informed about his/her assigned
group and the subsequent schedule within 1 week (by the
time of the first interventional treatment).
Randomization
Using the minimization method, participants will be ran-
domly assigned to either the intervention group or control
group. Central assignment involving an Internet-based
assignment system will be performed.
Participants will be randomly assigned to one of the two
groups according to the following factors:
1) Hospital
2) Gender
3) Age (< 40 or ≥ 40 years)
4) History of suicide attempts
Intervention
All participants will attend the semi-structured Psychoedu-
cation Program I, which will involve a discussion of psy-
chological changes leading to suicide, risk factors for
suicide and the relationship to psychiatric disorders;
introduce stress management; demonstrate the usefulness
of psychological and social support; and make patients
aware of social resources. After randomization, the fol-
lowing interventions will be carried out in the respective
groups (Table 1).
Case management intervention in the experimental group
Case managers will periodically contact participants
assigned to the experimental intervention group (on the
1st, 4th, 8th, and 12th week and the 6th month after the day
of written consent, and every 6 months thereafter until the
end of the study). Case managers will inform participants
about the date of their scheduled interviews in advance,
via e-mail or regular mail. E-mail messages for partici-
pants will be prepared with the e-mail form on the input
system and sent via the dedicated e-mail address for this
study; the dedicated e-mail address does not permit any
replies. Regular mail will be sent by participating hospi-
tals, and words such as suicide will not be printed on the
envelopes.
In principle, case management should be accomplished
through direct dialogue (face-to-face interviews), where a
telephone conversation is the next best option. Interviews
should be conducted at participating hospitals. If case
managers cannot reach participants, case managers will
approach participant family members who have given
their consent to be contacted in advance.
The interview scheduled for the first week should be con-
ducted within two days before or after the scheduled date.
Interviews for the 4th, 8th, and 12th weeks should be con-
ducted within a week, for the 6th month within 2 weeks,
and thereafter within 1 month before or after the sched-
uled date.
Case management will include the following activities:
1) Periodic interviews (either face-to-face or via tele-
phone) with participants
2) Collection of information about each participant's
background and treatment status
Flow diagram of the studyigure 1
Flow diagram of the study.
Patients who are admitted to emergency medical facilities and 
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pants
4) Coordination of appointments with psychiatrists and
primary care physicians
5) Encouragement of psychiatric treatment to the partici-
pants who have stopped receiving the treatment
6) Referrals to social resources and private support organ-
izations and coordination for utilization of these
resources
7) Providing information to participants and the Psychoed-
ucation Program II to their family members during hospi-
talization
8) Providing Internet-based information (website only for
the experimental intervention group)
Case managers will conduct periodic case conferences
with psychiatrists. The study group management office
and the intervention program committee will periodically
hold case conference meetings with the study group, visit
the participating hospitals, and meet with case managers,
as necessary.
Regarding Internet-based information, participants in the
experimental intervention group who access the website
will receive information about the psychoeducation pro-
gram, support organizations, and a self-diagnosis pro-
gram. The dedicated intervention website will contain
pages providing an introduction to social resources and
serial articles, applied intervention (including psychoedu-
cation and self-evaluation tools), and crisis intervention.
The Intervention Program Committee will periodically
update the content and articles on the website.
Standard treatment will be provided to subjects in the
experimental group at each participating hospital. In addi-
tion, each participant in the experimental group will
receive a pamphlet on suicide prevention following the
psychoeducation program and at hospital visits after
enrollment.
Control intervention
Participants in the control group will receive standard
treatment with casework at the participating hospitals.
Also, participants in the control group will receive a pam-
phlet on suicide prevention following the psychoeduca-
tion program and during their visits for periodic




Evaluators including psychiatrists, clinical psychologists,
psychiatric social workers, and/or other mental health
professionals, will conduct the psychiatric evaluations. In
order to conduct blinded evaluations, evaluators will not
know the participants' assigned groups, status of imple-
mentation of the intervention, or information on events
obtained by other on-site research staff. Moreover, to
achieve blinded evaluations, evaluators will not serve as
case managers or practitioners in charge of the Psychoedu-
cation Program II.
These evaluators will conduct psychiatric evaluations of
all participants enrolled at the hospitals and will use a case
sheet at 6 months from the date written consent was
obtained and every year thereafter until the completion of
the study. Evaluations can be carried out up to 1 month
before or after the scheduled date.
Evaluations generally will take place as face-to-face inter-
views at the participating hospitals. The evaluators will
notify the participants of the interview schedules 7 days
before the scheduled dates via e-mail or regular mail. E-
mail messages will be prepared with the e-mail form on
the input system and sent via the dedicated e-mail address
for this study; the dedicated email address does not permit
any replies. Regular mail will be sent by the participating
hospitals, and words such as suicide will not be printed on
the envelopes. The evaluators will schedule the next eval-
uation date and inform participants at the end of each
interview.
Evaluations will include the following:
1) Participant survival (or cause of death noted in the case
of death of the participant)
2) Whether or not suicidal behavior has been repeated
3) Any events other than (1) or (2)
4) Stress factors
5) Persons and/or organizations to consult
6) Treatment status (outpatient or inpatient)
7) Physical function
8) Drinking habits
9) Evaluations using scalesPage 6 of 11
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b) Beck Depression Inventory-II (BDI-II) [22]
c) SF-36 [23]
Events
Events will be classified as follows:
1) Recurrent suicidal behavior
2) Total deaths (from any cause)
3) Self-harm
4) Adverse events other than (1), (2), or (3): Any unfavo-
rable and unintended occurrence in a participant, whether
or not there is a causal relationship with the intervention,
will be recorded.
When identifying an event, the on-site research staff at the
participating hospital will record the information accord-
ing to the event review sheet and will confirm the infor-
mation with the investigator. If there are no
complications, the on-site research staff will enter the con-
tent of the event into the web input system. If necessary,
on-site research staff will consult with the on-site research
coordinator and the study group management office
regarding any aspects of the event that are unclear. The on-
site research coordinator will notify the hospital director
about any serious adverse event and will fax the event
review sheet directly to the study group management
office.
The data center will consolidate the input data and peri-
odically provide data to the study group management
office and the chairperson of the event review committee,
according to data management procedures. The study
group management office and the chairperson of the
event review committee should hold monthly event
review meetings to evaluate and assess details of events
based on the material provided.
Specific aspects of events will be described in the event
definitions and event review procedures.
Time periods during the study
Study period: August 2005 through March 2011
Enrollment period: July 2006 through December 2009
Follow-up period: July 2006 through June 2011
Preconditions for hospital participation in the study
A hospital satisfying the following preconditions may par-
ticipate in the study: The hospital should have both emer-
gency medicine and psychiatry departments and an
established collaborative agreement between those
departments, so that the hospital can provide patients
with psychiatric interventions to the emergency depart-
ment.
Within the enrollment period, the hospital can recruit and
obtain consent from at least 20 patients who are eligible
to participate in the context of inclusion and exclusion cri-
teria. The hospital will perform follow-up on the patients
until study completion.
All participating researchers should take a seminar on sui-
cide prevention (epidemiology, risk factors, psychology,
prevention, intervention, and postvention). According to
their respective roles, each participating researcher may
take other seminars on psychiatric diagnosis (Mini Inter-
national Neuropsychiatric Interview [M.I.N.I.; [24]]), the
psychoeducation program, psychiatric evaluation, and
assessment by scales (Suicide Intent Scale [18], Beck
Hopelessness Scale [21], BDI-II [22], and SF-36 [23]).
Approval of the study protocol
The study protocol will be reviewed and approved by the
Central Research Ethics Committee. In principle, the
study protocol also will have to be reviewed and approved
by the On-site Research Ethics Committee at each partici-
pating hospital.
Data collection
Data collection listed will be conducted according to the
appropriate timing and each aspect of the relevant infor-
mation.
Data collected at time of enrollment
1) Basic information on the participant
Initials, ID number, age, gender, other people living with
the participant, marital status, education, employment,
and other information
2) Information about suicidal behavior
Date and time, means, motivation, Beck Suicide Ideation
Scale, and other details of past suicidal behavior
3) Demographic status (items marked with an asterisk on
the forms are allocation adjustment factors): Age, gender,
history of suicide attempts, DSM-IV diagnosis with
M.I.N.I. [24], history of psychiatric treatment, history ofPage 7 of 11
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family history, and individuals to consult
4) Condition (psychiatric and physical diagnoses) at the
time of enrollment
a) Suicide Intent Scale (only at the time of enrollment)
[18]
b) Beck Hopelessness Scale [21]
c) BDI-II [22]
d) SF-36 [23]
Data collected at time of discharge
1) Date of hospital discharge
2) Discharge plans
Data collected during case management
1) Psychological and social conditions
2) Status of treatment for psychiatric and/or physical
problems
3) Utilization of social resources
4) Utilization of dedicated intervention website
5) Degree of participant satisfaction with case manage-
ment
Data collected during psychiatric evaluations
1) Participant survival (or cause of death of the partici-
pant)
2) Whether or not a suicidal behavior has been repeated
3) Any events other than (1) or (2)
4) Stress factors
5) Individuals and/or organizations to consult
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The incidence of first recurrent suicidal behavior
(expressed as attempted or completed suicides/person-
year) will be used as the primary outcome, because an
individual who reattempts suicide is at high risk for com-
pletion of suicide. Therefore, in order to develop effective
suicide prevention strategies, it is essential to measure the
time to the next suicidal behavior.
Secondary outcomes
Secondary outcomes will include the following:
1) Mortality rate (for any cause of death/person-year) dur-
ing the study period2) The number and incidence rate of
recurrent suicidal behavior, expressed as repeated suicidal
attempts/person-year
3) The number of self-harm behaviors
4) Types and numbers of individuals and/or organiza-
tions to consult
5) Other medical services received (during clinical visits
and/or hospital admission)
6) Physical function




The event review committee will assess events related to
the primary and secondary outcomes, while the assign-
ment of the participants remains blinded. The event
review committee will specify the evaluation criterion in
the event definitions and event review procedures.
Safety management
The on-site research staff at the participating hospitals will
take necessary and appropriate actions to ensure the safety
of participants when a serious adverse event occurs or a
participant is at impending risk of suicide during the
study. The on-site research staff will contact the on-site
research coordinator at the hospital, and the coordinatorPage 8 of 11
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tal and the study group management office.
Statistical analyses
Primary analysis
The primary objective of this study is to examine whether
or not the period of time until recurrent suicidal behavior
(either attempt or completion of suicide) of participants
in the experimental intervention group is significantly dif-
ferent from that of the control group. The stratified log-
rank test based on allocation factors will be performed for
all eligible participants in the intent-to-treat analysis, in
order to examine the null hypothesis that the two groups
are equal in the period of time until the incidence of the
event.
A one-sided test will be conducted, because there would
be no interest in the case that the experimental interven-
tion is found to be significantly inferior to standard treat-
ment. In this case, the level of significance will be set at
2.5% for the one-sided test, and the power will be set at
90%.
Sensitivity analyses will be performed as necessary, and a
regression analysis will be performed with risk factors of
potential influence.
Interim analyses
Interim analyses will be performed to evaluate achieve-
ment of the primary objective of the study. The analyses
will be conducted twice during the study. Participant
recruitment will be continued during the interim analyses.
For the interim analysis, the Lan-DeMets spending func-
tion will be used to adjust for multiplicity and to maintain
the alpha error of the overall study at 2.5% for the one-
sided test. The difference between the two groups in the
period up to the event occurrence, using the O'Brien-
Fleming alpha-spending function, will be examined for
statistical significance.
The study will be terminated if the period up to the event
occurrence in the trial intervention group exceeds that of
the control group and the p-value of the log-rank sum test
is less than the significance level defined by the method
described above.
Secondary analysis
Secondary outcomes will be examined in order to rein-
force the findings of the primary analysis. For analysis of
secondary outcomes, the period up to event occurrence
will be analyzed with the stratified log-rank test. Subgroup
analysis of the primary and secondary outcomes will be
performed by hospital, gender, age (< 40 or ≥ 40 years),
and occurrence of suicide attempt before enrollment in
this study. Because of the exploratory nature of the sec-
ondary analysis, no adjustment for multiplicity will be
made.
Ethical considerations
In this study, the rights and welfare of the participants will
be protected according to the World Medical Association
Declaration of Helsinki: Ethical Principles for Medical
Research Involving Human Subjects. The study will com-
ply with the ethical guidelines of the Ministry of Health,
Labour, and Welfare in Japan. Ethical validity, including
safety, scientific legitimacy, and reliability of results are
ensured. Personal information collected by the participat-
ing hospitals in this study will include no identifiers that
could be used to determine the identity of an individual
and, therefore, will be made anonymous.
Study monitoring
Periodic monitoring
The data management center will submit a monitoring
report, including the information listed below, to the J-
MISP administration office once every 3 months. The J-
MISP administration office will send the monitoring
reports to the study progress control committee, the Cen-
tral Research Ethics Committee, and the study group man-
agement office.
The study progress control committee will examine the
periodic monitoring reports and submit the evaluation to
the J-MISP director. As a third party, the central research
ethics committee will evaluate the periodic monitoring
reports and make recommendations to the J-MISP direc-
tor to revise the study protocol or stop the study, if ethical
problems, such as safety and efficacy issues, should arise.
Contents of monitoring reports
1) Progress of the study, including enrollment
2) Status of the implementation of psychiatric evaluations
3) Data on the occurrence of events (according to the
blinded group allocations)
4) Data on the occurrence of adverse events (according to
the blinded group allocations)
5) Other relevant information, such as presence of unde-
sirable issues and/or events
Revision of the study protocol and due process
The J-MISP director will immediately inform the
ACTION-J principal investigator of the decisions of the
central research ethics committee if the committee has rec-
ommended that the study protocol be revised due to the
emergence of safety issues based on the interim analysis,Page 9 of 11
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issues that might affect the conduct of the study. The
ACTION-J principal investigator will call a meeting of the
study group and discuss protocol revision based on the
decisions of the central research ethics committee. If nec-
essary, the principal investigator will propose the revised
study protocol and submit it to the J-MISP director.
If the study evaluation committee and the central research
ethics committee approve the revised protocol, the J-MISP
director will adopt the revised protocol after deliberation
in the steering committee. The study group management
office will immediately distribute the revised protocol to
all the on-site research staff through the on-site research
coordinator. The on-site research coordinator will submit
the revised study protocol to the on-site research ethics
committee at each participating hospital.
The study is to be resumed after the revised protocol has
been approved by each committee.
Study termination
Based on the findings of the interim analyses, the Central
Research Ethics Committee can make a recommendation
to the J-MISP director to terminate the study. The commit-
tee can decide to terminate the study because of safety
issues. This decision will be based on the findings of the
interim analyses, the periodic monitoring, the occurrence
of a serious adverse event, or other issues that possibly
could affect continuation of the study. The principal
investigator will promptly convene a meeting of the steer-
ing committee to consider whether this study should be
terminated, according to the conclusion of the central
research ethics committee. Then, if study termination is
confirmed to be appropriate, the final decision will be
made.
Discussion
Suicide is a complex phenomenon that encompasses mul-
tiple factors. Ratios between 10 and 18 suicide attempts to
1 completed suicide have been estimated in other coun-
tries [25,26]. Although the ratio of suicide attempts to
completed suicide is not known in Japan, many patients
with self-injury from suicide attempts are transported to
emergency departments in Japan [5].
In the absence of effective measures against suicide
attempters, it has been difficult to reverse an increasing
suicide trend in Japan. Case management by multi-sector
collaboration is required.
The ACTION-J study is designed to evaluate the effective-
ness of emergency facility-based case management for sui-
cide prevention in 19 participating hospitals in Japan.
ACTION-J is intended to provide valuable information on
suicide attempters and to develop effective case manage-
ment to reduce future risk for suicide attempters.
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